Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Bimal K, Malhotra"'
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 48:257-269
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5bf0e99ac883c753acf31c90ce4d33b
https://doi.org/10.1007/s13318-023-00818-8
https://doi.org/10.1007/s13318-023-00818-8
Autor:
Jonathan N. Bauman, Angela C. Doran, Amanda King-Ahmad, Raman Sharma, Gregory S. Walker, Jian Lin, Tsung H. Lin, Jean-Baptiste Telliez, Sakambari Tripathy, Theunis C. Goosen, Christopher Banfield, Bimal K. Malhotra, Martin E. Dowty
Publikováno v:
Drug Metabolism and Disposition. 50:1106-1118
Abrocitinib is an oral once-daily Janus kinase 1 selective inhibitor being developed for the treatment of moderate-to-severe atopic dermatitis. This study examined the disposition of abrocitinib in male participants following oral and intravenous adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926208d526384181f37cc80f92c02aa6
https://doi.org/10.1124/dmd.122.000829
https://doi.org/10.1124/dmd.122.000829
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 10 (2019)
Background: Abuse of prescription opioids, particularly by intravenous (IV) administration, can cause respiratory depression and death. ALO-02, an abuse-deterrent opioid formulation, is designed to release sequestered naltrexone upon manipulation by
Externí odkaz:
https://doaj.org/article/e4280abc13a748d0adc00eb6928d629e
Autor:
Jessica, Wojciechowski, Bimal K, Malhotra, Xiaoxing, Wang, Luke, Fostvedt, Hernan, Valdez, Timothy, Nicholas
Publikováno v:
British Journal of Clinical Pharmacology. 88:3856-3871
Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate-to-severe atopic dermatitis. Herein we describe the time-course of drug-induced platelet reduction following abrocitinib administration, identify covariates affecting p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e8274614bd4531f07ec74fa6928599
https://doi.org/10.1111/bcp.15334
https://doi.org/10.1111/bcp.15334
Autor:
Xiaoxing, Wang, Martin E, Dowty, Ann, Wouters, Svitlana, Tatulych, Carol A, Connell, Vu H, Le, Sakambari, Tripathy, Melissa T, O'Gorman, Jennifer A, Winton, Natalie, Yin, Hernan, Valdez, Bimal K, Malhotra
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 47:419-429
Abrocitinib is a Janus kinase 1-selective inhibitor for the treatment of moderate-to-severe atopic dermatitis. Abrocitinib is eliminated primarily by metabolism involving cytochrome P450 (CYP) enzymes. Abrocitinib pharmacologic activity is attributab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d9f03f3e879e1fde1420371ca744bcb
https://doi.org/10.1007/s13318-021-00745-6
https://doi.org/10.1007/s13318-021-00745-6
Autor:
Jessica Wojciechowski, Bimal K. Malhotra, Xiaoxing Wang, Luke Fostvedt, Hernan Valdez, Timothy Nicholas
Publikováno v:
Clinical Pharmacokinetics. 61:709-723
Abrocitinib is a Janus kinase 1 inhibitor in development for the treatment of atopic dermatitis (AD). This work characterized orally administered abrocitinib population pharmacokinetics in healthy individuals, patients with psoriasis, and patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bb3991194813b18a809f679e5e23eeb
https://doi.org/10.1007/s40262-021-01104-z
https://doi.org/10.1007/s40262-021-01104-z
Autor:
Xiaoxing Wang, Pankaj Gupta, Bimal K. Malhotra, Saleem Ashley Farooqui, Vu H. Le, Jessica Wojciechowski, Arnab Mukherjee, Timothy Nicholas
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(9)
Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate to severe atopic dermatitis (AD). To assess the relationship between abrocitinib plasma concentrations and heart rate (HR)-corrected QT (QTc) and HR and calculate the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c4c1ba67ca866a9fa1de979ea3107b
https://pubmed.ncbi.nlm.nih.gov/35532896
https://pubmed.ncbi.nlm.nih.gov/35532896
Autor:
Ellen Q. Wang, Vu Le, Jennifer A. Winton, Sakambari Tripathy, Sangeeta Raje, Lisy Wang, Martin E. Dowty, Bimal K. Malhotra
Publikováno v:
Journal of clinical pharmacology. 62(4)
Abrocitinib, an oral once-daily Janus kinase 1 selective inhibitor, is under development for the treatment of atopic dermatitis. This phase 1, nonrandomized, open-label, single-dose study (NCT03660241) investigated the effect of renal impairment on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b6c1d7f83e415dc4e403f8ffca89996
https://pubmed.ncbi.nlm.nih.gov/34637151
https://pubmed.ncbi.nlm.nih.gov/34637151
Autor:
Jessica Wojciechowski, Bimal K. Malhotra, Xiaoxing Wang, Luke Fostvedt, Hernan Valdez, Timothy Nicholas
Publikováno v:
Clinical Pharmacokinetics. 61:591-591
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61fa4070170d749ab289fe1b0478667d
https://doi.org/10.1007/s40262-022-01112-7
https://doi.org/10.1007/s40262-022-01112-7
Publikováno v:
Journal of Drug Targeting. 4:277-288
EAB 515 (S-alpha-amino-5-phosphonomethyl[1,1'biphenyl]-3-propanoic acid) is an extremely hydrophilic N-methyl-D-aspartate antagonist. It shows marked CNS activity, in that it is a potent neuroprotector in models of cerebral ischemia, and also demonst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::203f3316f8b1431d4cce41ae13ae26a6
https://doi.org/10.3109/10611869708995843
https://doi.org/10.3109/10611869708995843